

From: [REDACTED] (SANTE)

Sent: 30 March 2017 22:40

To: CHAZE Nathalie (CAB-ANDRIUKAITIS); JUELICHER Sabine (SANTE); MIKO Ladislav (SANCO)

Cc: [REDACTED] (SANCO); [REDACTED] (SANCO); [REDACTED] (SANCO); [REDACTED] (SANCO); [REDACTED] (SANTE); [REDACTED] (SANCO); [REDACTED] (SANTE); [REDACTED] (SANCO); [REDACTED] (SANCO); [REDACTED] (SANCO); [REDACTED] (SANTE); [REDACTED] [@ec.europa.eu](mailto:[REDACTED]@ec.europa.eu)

Subject: BTO about meeting N. Chaze with Bayer, 29 March 2017

Participants

© 2006 The Authors
Journal compilation © 2006 Blackwell Publishing Ltd

11/11/2016

Meeting was requested by Bayer, with objective to introduce new Head of Bayer office in Brussels, Mr

1. Endocrine disruptors

Bayer considers technical amendment to annex as crucial, furthermore potency important. We urged them to reconsider position and to accept the proposed option based on WHO definition alone as this would address the current uncertainty due to the interim criteria. The derogation should be discussed at a later stage once criteria are adopted. NC stressed that derogation is an institutional issue for Parliament; this view is not shared by Bayer. Bayer would favour if COM could consider to open discussion on CMR as well in case derogation is discussed at a later stage.

Government	Percentage
Current government	85%
Previous government	15%

Service	Percentage
Online banking	100%
Mobile banking	95%
ATM	90%
Branch	85%
Mobile app	75%

Government	Percentage
Current government	85%
Previous government	15%

